NCT06934577Recruiting
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine- SIGHT 2: A Pragmatic Randomized Trial
Source: ClinicalTrials.gov · Last updated 15 Dec 2025
Brief summary (registry, in English)
To compare eye disease detection rates at a Federally Qualified Health Center between a technology-enhanced protocol and standard optometric clinical examination for three of the leading causes of blindness: glaucoma, diabetic retinopathy, and visually significant cataract.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 900 (estimated)
- First submitted
- 10 Apr 2025
- Start date
- 4 Dec 2025
- Primary completion date
- Aug 2030
- Lead sponsor
- University of Michigan
- Diseases
- Glaucoma
- NCT number
- NCT06934577
What you commit to
- Study type: Interventional
- Planned participants: 900
- From 4 Dec 2025 to the primary completion date, Aug 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previously declined participation
Other illness
- cognitive impairment
Other
- significant eye pain
- sudden decrease in vision within one week
- binocular diplopia
- pregnancy
Who the study is looking for
- Speak English, Spanish, Arabic, Chinese, French, Hindi, Finnish, Albanian, Russian or Tagalog
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hamilton Optometry Clinic Coordinator of this site? Confirm its status | Flint | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.